Systems biology of lupus: Mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment

References

• Tenbrock K, Juang YT, Kyttaris VC, Tsokos GC. Altered signal transduction in SLE T cells. Rheumatology. 2007; 46 10: 1525–1530 [Review] [78 refs].
   PubMed Web of Science ®Google Scholar
• Jenks SA, Sanz Ia. Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev. 2009; 8 3: 209–213.
   PubMed Web of Science ®Google Scholar
• Pascual V, Banchereau J, Palucka AK. The central role of dendritic cells and interferon-alpha in SLE. Curr Opin Rheumatol. 2003; 15 5: 548–556 [Review] [79 refs].
   PubMed Web of Science ®Google Scholar
• Crispin JC, Alcocer-Varela J. The role myeloid dendritic cells play in the pathogenesis of systemic lupus erythematosus. Autoimmun Rev. 2007; 6:450–456 [Review] [40 refs].
   PubMed Web of Science ®Google Scholar
• Kyttaris VC, Juang YT, Tsokos GC. Immune cells and cytokines in systemic lupus erythematosus: An update. Curr Opin Rheumatol. 2005; 17:518–522 [see comment]. [Review] [29 refs].
   PubMed Web of Science ®Google Scholar
• Gergely PJ, Grossman C, Niland B, Puskas F, Neupane H, Allam F, . Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arth Rheum. 2002; 46:175–190.
   PubMed Web of Science ®Google Scholar
• Perl A, Gergely PJr., Nagy G, Koncz A, Banki K. Mitochondrial hyperpolarization: A checkpoint of T cell life, death, and autoimmunity. Trends Immunol. 2004; 25:360–367.
   PubMed Web of Science ®Google Scholar
• Ma L, Chan KW, Trendell-Smith NJ, Wu A, Tian L, Lam AC, . Systemic autoimmune disease induced by dendritic cells that have captured necrotic but not apoptotic cells in susceptible mouse strains. Eur J Immunol. 2005; 35:3364–3375.
   PubMedGoogle Scholar
• Nambiar MP, Fisher CU, Warke VG, Krishnan S, Mitchell JP, Delaney N, . Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arth Rheum. 2003; 48:1948–1955.
   PubMedGoogle Scholar
• Kyttaris VC, Krishnan S, Tsokos GC. Systems biology in systemic lupus erythematosus: Integrating genes, biology and immune function. Autoimmunity. 2006; 39 8: 70–79.
   Google Scholar
• Nagy G, Ward J, Mosser DD, Koncz A, Gergely P, Stancato C, . Regulation of CD4 expression via recycling by HRES-1/RAB4 controls susceptibility to HIV infection. J Biol Chem. 2006; 281:34574–34591.
   PubMed Web of Science ®Google Scholar
• Fernandez DR, Telarico T, Bonilla E, Li Q, Banerjee S, Middleton FA, . Activation of mTOR controls the loss of TCR in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol. 2009; 182:2063–2073.
   PubMed Web of Science ®Google Scholar
• Wu T, Qin X, Kurepa Z, Kumar KR, Liu K, Kanta H, . Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus. J Clin Invest. 2007; 117 8: 2186–2196 [Article].
   PubMed Web of Science ®Google Scholar
• Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC. B Cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest. 1996; 98 11: 2549–2557 [Article].
   PubMed Web of Science ®Google Scholar
• Skulachev VP. Mitochondrial physiology and pathology; concepts of programmed death of organelles, cells and organisms. Mol Asp Med. 1999; 20:139–140.
   PubMedGoogle Scholar
• Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Ann Rev Immunol. 2009; 27 1: 591–619.
   PubMed Web of Science ®Google Scholar
• Otsuji M, Kimura Y, Aoe T, Okamoto Y, Saito T. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc Natl Acad Sci USA. 1996; 93:13119–13124.
   PubMed Web of Science ®Google Scholar
• Koretzky GA, Boerth NJ. The role of adapter proteins in T cell activation. Cell Mol Life Sci. 1999; 56:1048–1060 [Review] [137 refs].
   PubMedGoogle Scholar
• Beiqing L, Chen M, Whisler RL. Sublethal levels of oxidative stress stimulate transcriptional activation of c-jun and suppress IL-2 promoter activation in Jurkat T cells. J Immunol. 1996; 157:160–169.
   PubMed Web of Science ®Google Scholar
• Furuke K, Shiraishi M, Mostowski HS, Bloom ET. Fas ligand induction in human NK cells is regulated by redox through a calcineurin-nuclear factors of activated T cell-dependent pathway. J Immunol. 1999; 162:1988–1993.
   PubMedGoogle Scholar
• Juang YT, Wang Y, Jiang G, Peng HB, Ergin S, Finnell M, . PP2A dephosphorylates Elf-1 and determines the expression of CD3{zeta} and FcR{gamma} in human systemic lupus erythematosus T cells. J Immunol. 2008; 181 5: 3658–3664.
   PubMedGoogle Scholar
• Sunahori K, Juang YT, Tsokos GC. Methylation status of CpG islands flanking a cAMP response element motif on the protein phosphatase 2Ac{alpha} promoter determines CREB binding and activity. J Immunol. 2009; 182 3: 1500–1508.
   PubMedGoogle Scholar
• Franco R, Schoneveld O, Georgakilas AG, Panayiotidis MI. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett. 2008; 266 1: 6–11.
   PubMed Web of Science ®Google Scholar
• Carballo M, Conde M, El Bekay R, Martin-Nieto J, Camacho MJ, Monteseirin J, . Oxidative stress triggers STAT3 tyrosine phosphorylation and nuclear translocation in human lymphocytes. J Biol Chem. 1999; 274 25: 17580–17586.
   PubMed Web of Science ®Google Scholar
• Harada T, Kyttaris V, Li Y, Juang YT, Wang Y, Tsokos GC. Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration. Autoimmunity. 2007; 40:1–8.
   PubMed Web of Science ®Google Scholar
• de Beaucoudrey L, Puel A, Filipe-Santos O, Cobat A, Ghandil P, Chrabieh M, . Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med. 2008; 205 7: 1543–1550.
   PubMed Web of Science ®Google Scholar
• Jacob N, Yang H, Pricop L, Liu Y, Gao X, Zheng SG, . Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol. 2009; 182 4: 2532–2541.
   PubMed Web of Science ®Google Scholar
• Crispin JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, . Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol. 2008; 181 12: 8761–8766.
   PubMed Web of Science ®Google Scholar
• Warner LM, Adams LM, Sehgal SN. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arth Rheum. 1994; 37:289–297.
   PubMed Web of Science ®Google Scholar
• Desai BN, Myers BR, Schreiber SL. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc Natl Acad Sci USA. 2002; 99:4319–4324.
   PubMed Web of Science ®Google Scholar
• Fernandez D, Bonilla E, Mirza N, Perl A. Rapamycin reduces disease activity and normalizes T-cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arth Rheum. 2006; 54 9: 2983–2988.
   PubMed Web of Science ®Google Scholar
• Kirken RA, Wang YL. Molecular actions of sirolimus: Sirolimus and mTor. Transplant Proc. 2003; 35 3: 227S–230S [Review] [32 refs].
   PubMed Web of Science ®Google Scholar
• Fernandez D, Perl A. Metabolic control of T cell activation and death in SLE. Autoimmun Rev. 2009; 8:184–189.
   PubMed Web of Science ®Google Scholar
• Liu K, Mohan C. Altered B-cell signaling in lupus. Autoimmun Rev. 2009; 8 3: 214–218.
   PubMedGoogle Scholar
• Pua HH, Guo J, Komatsu M, He YW. Autophagy is essential for mitochondrial clearance in mature T lymphocytes. J Immunol. 2009; 182 7: 4046–4055.
   PubMed Web of Science ®Google Scholar
• Kundu M, Thompson CB. Macroautophagy versus mitochondrial autophagy: A question of fate?. Cell Death Differ. 2005; 12 Suppl. 2: 1484–1489 [Review] [58 refs].
   PubMedGoogle Scholar
• Juntilla MM, Koretzky GA. Critical roles of the PI3K/Akt signaling pathway in T cell development. Immunol Lett. 2008; 116 2: 104–110.
   PubMedGoogle Scholar
• Barber DF, Bartolome A, Hernandez C, Flores JM, Fernandez-Arias C, Rodriguez-Borlado L, . Class IB-phosphatidylinositol 3-kinase (PI3K) deficiency ameliorates IA-PI3K-induced systemic lupus but not T cell invasion. J Immunol. 2006; 176 1: 589–593.
   PubMedGoogle Scholar
• Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. Impaired Fas response and autoimmunity in Pten+/mice. Science. 1999; 285 5436: 2122–2125.
   PubMedGoogle Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307:1098–1101.
   PubMed Web of Science ®Google Scholar
• Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+cells. J Exp Med. 2008; 13:565–574.
   Google Scholar
• Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, . T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci USA. 2008; 105 22: 7797–7802.
   PubMed Web of Science ®Google Scholar
• Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol. 2007; 178 4: 2579–2588.
   PubMed Web of Science ®Google Scholar
• Hahn BH, Anderson M, Le E, La Cava A. Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients. Arth Rheum. 2008; 58 8: 2488–2497.
   PubMedGoogle Scholar
• Rink J, Ghigo E, Kalaidzidis Y, Zerial M. Rab conversion as a mechanism of progression from early to late endosomes. Cell. 2005; 122 5: 735–749.
   PubMed Web of Science ®Google Scholar
• van der Sluis P, Hull M, Webster P, Male P, Goud B, Mellman I. The small GTP-binding protein rab4 controls an early sorting event on the endocytic pathway. Cell. 1992; 70:729–740.
   PubMedGoogle Scholar
• Saito T, Jones CC, Huang S, Czech MP, Pilch PF. The interaction of Akt with APPL1 is required for insulin-stimulated Glut4 translocation. J Biol Chem. 2007; 282 44: 32280–32287.
   PubMedGoogle Scholar
• Jiang X, Kenerson H, Aicher L, Miyaoka R, Eary J, Bissler J, . The tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptake. Am J Pathol. 2008; 172 6: 1748–1756.
   PubMedGoogle Scholar
• Edinger AL, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell. 2002; 13 7: 2276–2288.
   PubMed Web of Science ®Google Scholar
• Meusser B, Sommer T. Vpu-mediated degradation of CD4 reconstituted in yeast reveals mechanistic differences to cellular ER-associated protein degradation. Mol Cell. 2004; 14:247–258.
   PubMed Web of Science ®Google Scholar
• Kyttaris VC, Tsokos GC. T lymphocytes in systemic lupus erythematosus: An update. Curr Opin Rheumatol. 2004; 16:548–552 [Review] [36 refs].
   PubMed Web of Science ®Google Scholar
• Perl A, Isaacs CM, Eddy RL, Byers MG, Sait SN, Shows TB. The human T-cell leukemia virus-related endogenous sequence (HRES1) is located on chromosome 1 at q42. Genomics. 1991; 11:1172–1173.
   PubMedGoogle Scholar
• Magistrelli C, Banki K, Ferrante P, Perl A. Mapping and cloning of polymorphic genotypes of the HRES-1 LTR. Arth Rheum. 1994; 37:S316.
   PubMedGoogle Scholar
• Magistrelli C, Samoilova E, Agarwal RK, Banki K, Ferrante P, Vladutiu A, . Polymorphic genotypes of the HRES-1 human endogenous retrovirus locus correlate with systemic lupus erythematosus and autoreactivity. Immunogenetics. 1999; 49:829–834.
   PubMed Web of Science ®Google Scholar
• Pullmann RJr., Bonilla E, Phillips PE, Middleton FA, Perl A. Haplotypes of the HRES-1 endogenous retrovirus are associated with development and disease manifestations of systemic lupus erythematosus. Arth Rheum. 2008; 58:532–540.
   PubMedGoogle Scholar
• Nagy G, Barcza M, Gonchoroff N, Phillips PE, Perl A. Nitric oxide-dependent mitochondrial biogenesis generates Ca2+ signaling profile of lupus T cells. J Immunol. 2004; 173 6: 3676–3683.
   PubMed Web of Science ®Google Scholar
• Vassilopoulos D, Kovacs B, Tsokos GC. TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol. 1995; 155 4: 2269–2281.
   PubMedGoogle Scholar
• Jury EC, Kabouridis PS, Flores-Borja F, Mageed RA, Isenberg DA. Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J Clin Invest. 2004; 113:1176–1187.
   PubMed Web of Science ®Google Scholar
• Jury EC, Kabouridis PS, Abba A, Mageed RA, Isenberg DA. Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. Arth Rheum. 2003; 48:1343–1354.
   PubMed Web of Science ®Google Scholar
• Flores-Borja F, Kabouridis PS, Jury EC, Isenberg DA, Mageed RA. Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus. Arth Rheum. 2007; 56 1: 291–302 [Article].
   PubMed Web of Science ®Google Scholar
• Flores-Borja FP, Kabouridis PSP, Jury ECP, Isenberg DAM, Mageed RAP. Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arth Rheum. 2005; 52 12: 3955–3965 [Article].
   PubMed Web of Science ®Google Scholar
• MacMillan D, Currie S, Bradley KN, Muir TC, McCarron JG. In smooth muscle, FK506-binding protein modulates IP3 receptor-evoked Ca2+release by mTOR and calcineurin. J Cell Sci. 2005; 118:5443–5451.
   PubMed Web of Science ®Google Scholar
• Haraldsson MK, Louis-Dit-Sully CA, Lawson BR, Sternik G, Santiago-Raber ML, Gascoigne NRJ, . The lupus-related Lmb3 locus contains a disease-suppressing Coronin-1A gene mutation. Immunity. 2008; 28 1: 40–51.
   PubMed Web of Science ®Google Scholar
• Anolik J, Sanz I. B cells in human and murine systemic lupus erythematosus. Curr Opin Rheumatol. 2004; 16:505–512 [Review] [73 refs].
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, . Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003; 349 16: 1526–1533 [Article].
   PubMed Web of Science ®Google Scholar
• James JJ, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJA, Harley JB. An increased prevalence of Epstein–Barr virus infection in young patientts suggests a possible etiology for systemic lupus erythematosus. J Clin Invest. 1997; 100:3019–3026.
   PubMed Web of Science ®Google Scholar
• James JA, Gross T, Scofield RH, Harley JB. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B′-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med. 1995; 181:453–461.
   PubMedGoogle Scholar
• Pugh-Bernard AE, Cambier JC. B cell receptor signaling in human systemic lupus erythematosus. Curr Opin Rheumatol. 2006; 18 5: 451–455 [Miscellaneous].
   PubMedGoogle Scholar
• Cappione AIII, Anolik JH, Pugh-Bernard A, Barnard J, Dutcher P, Silverman G, . Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest. 2005; 115:3205–3216.
   PubMed Web of Science ®Google Scholar
• Cappione AJ, Pugh-Bernard AE, Anolik JH, Sanz I. Lupus IgG VH4.34 antibodies bind to a 220-kDa glycoform of CD45/B220 on the surface of human B lymphocytes. J Immunol. 2004; 172:4298–4307.
   PubMed Web of Science ®Google Scholar
• Nicholas MW, Dooley MA, Hogan SL, Anolik J, Looney J, Sanz I, . A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. Clin Immunol. 2008; 126 2: 189–201.
   PubMedGoogle Scholar
• Hasler P, Zouali M. B cell receptor signaling and autoimmunity. FASEB J. 2001; 15 12: 2085–2098.
   PubMed Web of Science ®Google Scholar
• Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R, . Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell. 1995; 83 2: 301–311.
   PubMed Web of Science ®Google Scholar
• Nishizumi H, Horikawa K, Mlinaric-Rascan I, Yamamoto T. A double-edged kinase Lyn: A positive and negative regulator for antigen receptor-mediated signals. J Exp Med. 1998; 187 8: 1343–1348 [Report].
   PubMed Web of Science ®Google Scholar
• Hibbs ML, Harder KW, Armes J, Kountouri N, Quilici C, Casagranda F, . Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J Exp Med. 2002; 196 12: 1593–1604.
   PubMed Web of Science ®Google Scholar
• Enyedy EJ, Mitchell JP, Nambiar MP, Tsokos GC. Defective Fc[gamma]RIIb1 signaling contributes to enhanced calcium response in B Cells from patients with systemic lupus erythematosus. Clin Immunol. 2001; 101 2: 130–135.
   PubMedGoogle Scholar
• Tuscano JM, Hsu TC, McKnight H, Ansari AA, Gershwin ME. Phosphorylation abnormalities: NZB mice exhibit a B-cell signalling defect. J Autoimmun. 2002; 19 3: 103–109.
   PubMedGoogle Scholar
• Kono H, Kyogoku C, Suzuki T, Tsuchiya N, Honda H, Yamamoto K, . Fc{gamma}RIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet. 2005; 14 19: 2881–2892.
   PubMedGoogle Scholar
• Floto RA, Clatworthy MR, Heilbronn KR, Rosner DR, MacAry PA, Rankin A, . Loss of function of a lupus-associated Fc[gamma]RIIb polymorphism through exclusion from lipid rafts. Nat Med. 2005; 11 10: 1056–1058.
   PubMed Web of Science ®Google Scholar
• Majeti R, Xu Z, Parslow TG, Olson JL, Daikh DI, Killeen N, . An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell. 2000; 103 7: 1059–1070.
   PubMedGoogle Scholar
• Gupta VA, Hermiston ML, Cassafer G, Daikh DI, Weiss A. B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and Fas deficiency. J Exp Med. 2008; 205 12: 2755–2761.
   PubMedGoogle Scholar
• Zikherman J, Hermiston M, Steiner D, Hasegawa K, Chan A, Weiss A. PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. J Immunol. 2009; 182 7: 4093–4106.
   PubMed Web of Science ®Google Scholar
• Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, Kern M, . Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: The PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet. 2005; 76 4: 561–571.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA. 2002; 99 1: 351–358 [Review] [186 refs].
   PubMed Web of Science ®Google Scholar
• Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, . Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: Implications for the pathogenesis of SLE. J Exp Med. 2008; 205 13: 3007–3018.
   PubMed Web of Science ®Google Scholar
• Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 19192: 225–234.
   Google Scholar
• Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity. 2006; 25:383–392 [Review] [100 refs].
   PubMed Web of Science ®Google Scholar
• Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, . A modular analysis framework for blood genomics studies: Application to systemic lupus erythematosus. Immunity. 2008; 29:150–164.
   PubMed Web of Science ®Google Scholar
• Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, . Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003; 197 6: 711–723 [comment].
   PubMed Web of Science ®Google Scholar
• Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA. 2003; 100 5: 2610–2615.
   PubMed Web of Science ®Google Scholar
• Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arth Rheum. 2005; 52:1491–1503.
   PubMed Web of Science ®Google Scholar
• Banki K, Hutter E, Gonchoroff N, Perl A. Elevation of mitochondrial transmembrane potential and reactive oxygen intermediate levels are early events and occur independently from activation of caspases in Fas signaling. J Immunol. 1999; 162:1466–1479.
   PubMed Web of Science ®Google Scholar
• Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA, . Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet. 2007; 39 9: 1065–1067.
   PubMed Web of Science ®Google Scholar
• Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell. 2008; 134 4: 587–598 [see comment].
   PubMed Web of Science ®Google Scholar
• Krieg AM, Gourley MF, Perl A. Endogenous retroviruses: Potential etiologic agents in autoimmunity. FASEB J. 1992; 6:2537–2544 [Review].
   PubMed Web of Science ®Google Scholar
• Perl A, Banki K. Human endogenous retroviral elements and autoimmunity: Data and concepts. Trends Microbiol. 1993; 1:153–156.
   PubMedGoogle Scholar
• Perl A. Role of endogenous retroviruses in autoimmune diseases. Rheum Dis Clin North Am. 2003; 29 1: 123–143 [Review] [177 refs].
   PubMed Web of Science ®Google Scholar
• Llorente L, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Maillot MC, Durand-Gasselin I, . Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw. 1993; 4:421–427.
   PubMed Web of Science ®Google Scholar
• Georgescu L, Vakkalanka RK, Elkon KB, Crow MK. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J Clin Invest. 1997; 100:2622–2633.
   PubMed Web of Science ®Google Scholar
• Gergely PJ, Niland B, Gonchoroff N, Pullmann RJr., Phillips PE, Perl A. Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus. J Immunol. 2002; 169:1092–1101.
   PubMed Web of Science ®Google Scholar
• Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, . Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med. 1995; 181:839–844.
   PubMed Web of Science ®Google Scholar
• Kovacs B, Vassilopoulos D, Vogelgesang SA, Tsokos GC. Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: Role of decreased intracellular TNF-alpha. Clin Immunol Immunopathol. 1996; 81:293–302.
   PubMedGoogle Scholar
• Jacob CO, McDevitt HO. Tumour necrosis factor-[alpha] in murine autoimmune ‘lupus’ nephritis. Nature. 1988; 331 6154: 356–358.
   PubMed Web of Science ®Google Scholar
• Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open-label study. Arth Rheum. 2004; 50 10: 3161–3169.
   PubMed Web of Science ®Google Scholar
• Aringer M, Steiner G, Graninger WB, Hofler E, Steiner CW, Smolen JS. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arth Rheum. 2007; 56 1: 247.
   Google Scholar
• Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L, . Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. Medicine. 2007; 86 4: 242–251.
   PubMed Web of Science ®Google Scholar
• Mackay F, Browning JL. BAFF: A fundamental survival factor for B cells. Nat Rev Immunol. 2002; 2 7: 465–475 [Review] [79 refs].
   PubMed Web of Science ®Google Scholar
• Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, . Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 19011: 1697–1710.
   Google Scholar
• Liu W, Szalai A, Zhao L, Liu D, Martin F, Kimberly RP, . Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arth Rheum. 2004; 50 6: 1884–1896.
   PubMedGoogle Scholar
• Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arth Rheum. 2001; 44 6: 1313–1319.
   PubMed Web of Science ®Google Scholar
• Carter RH, Zhao H, Liu X, Pelletier M, Chatham W, Kimberly R, . Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arth Rheum. 2005; 52 12: 3943–3954.
   PubMedGoogle Scholar
• Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, . Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 1920; 20 6: 785–798 [see comment].
   Google Scholar
• Clementi E, Brown GC, Feelisch M, Moncada S. Persistent inhibition of cell respiration by nitric oxide: Crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci USA. 1998; 95 13: 7631–7636.
   PubMed Web of Science ®Google Scholar
• Perl A, Gergely PJr., Puskas F, Banki K. Metabolic switches of T-cell activation and apoptosis. Antiox Redox Signal. 2002; 4 5: 427–443.
   PubMedGoogle Scholar
• Suwannaroj S, Lagoo A, Keisler D, McMurray RW. Antioxidants suppress mortality in the female NZB × NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus. 2001; 10 4: 258–265.
   PubMed Web of Science ®Google Scholar
• Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, . High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005; 353:2229–2242 [see comment].
   PubMed Web of Science ®Google Scholar
• Ibiza S, Victor VM, Bosca I, Ortega A, Urzainqui A, O'Connor JE, . Endothelial nitric oxide synthase regulates T cell receptor signaling at the immunological synapse. Immunity. 2006; 24 6: 753–765.
   PubMedGoogle Scholar
• Weinberg JB, Granger DL, Pisetsky DS, Seldin MF, Misukonis MA, Mason SN, . The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: Increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-l-arginine. J Exp Med. 1994; 179:651–660.
   PubMed Web of Science ®Google Scholar
• Gilkeson GS, Mudgett JS, Seldin MF, Ruiz P, Alexander AA, Misukonis MA, . Clinical and serologic manifestations of autoimmune disease in MRL-lpr/lpr mice lacking nitric oxide synthase type 2. J Exp Med. 1997; 186:365–373.
   PubMedGoogle Scholar
• Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006; 177 12: 8338–8347.
   PubMed Web of Science ®Google Scholar
• Golovina TN, Mikheeva T, Suhoski MM, Aqui NA, Tai VC, Shan X, . CD28 costimulation is essential for human T regulatory expansion and function. J Immunol. 2008; 181 4: 2855–2868.
   PubMed Web of Science ®Google Scholar
• Enyedy EJ, Nambiar MP, Liossis SN, Dennis G, Kammer GM, Tsokos GC. Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arth Rheum. 2001; 44:1114–1121.
   PubMed Web of Science ®Google Scholar
• Krishnan S, Juang YT, Chowdhury B, Magilavy A, Fisher CU, Nguyen H, . Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol. 2008; 181 11: 8145–8152.
   PubMed Web of Science ®Google Scholar
• Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, . An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arth Rheum. 2008; 58 5: 1433–1444.
   PubMed Web of Science ®Google Scholar
• Sanz I, Anolik J. Reconstitution of the adult B cell repertoire after treatment with rituximab. Arth Res Ther. 2005; 7:175–176 [comment].
   PubMedGoogle Scholar
• Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, . Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis. 2008; 67 12: 1724–1731.
   PubMed Web of Science ®Google Scholar
• Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, . Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arth Rheum. 2004; 50:3580–3590.
   PubMed Web of Science ®Google Scholar
• Boletis JN, Marinaki S, Skalioti C, Lionaki SS, Iniotaki A, Sfikakis PP. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: A long-term prospective study. Nephrol Dial Transplant. 20092157–2160 DOI:10.1093/ndt/gfp002.
   PubMedGoogle Scholar
• Kumar S, Benseler SM, Kirby-Allen M, Silverman ED. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics. 2009; 123 1: 159–163.
   Google Scholar
• Halpern WG, Lappin P, Zanardi T, Cai W, Corcoran M, Zhong J, . Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci. 2006; 91 2: 586–599.
   PubMed Web of Science ®Google Scholar
• Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, . Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: A phase I trial in patients with systemic lupus erythematosus. Arthr Res Ther. 2008; 10 5: R109.
   Web of Science ®Google Scholar
• Yi Y, McNerney M, Datta SK. Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol. 2000; 165 11: 6627–6634.
   PubMedGoogle Scholar
• Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol. 1997; 159 7: 3104–3108.
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Davis JCJr., Merrill JT, Totoritis MC, Wofsy D. Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. Arth Rheum. 2002; 46 12: 3251–3258.
   PubMed Web of Science ®Google Scholar
• Mount GR, Gilliland WR. Emerging biological therapies in systemic lupus erythematosus. Clin Pharmacol Ther. 2007; 83 1: 167–171.
   PubMedGoogle Scholar
• Schiffer L, Bethunaickan R, Ramanujam M, Huang W, Schiffer M, Tao H, . Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol. 2008; 180 3: 1938–1947.
   PubMed Web of Science ®Google Scholar
• Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 1994; 179:1317–1330.
   PubMed Web of Science ®Google Scholar
• Banki K, Hutter E, Colombo E, Gonchoroff NJ, Perl A. Glutathione levels and sensitivity to apoptosis are regulated by changes in transaldolase expression. J Biol Chem. 1996; 271:32994–33001.
   PubMed Web of Science ®Google Scholar
• Leist M, Single B, Castoldi AF, Kuhnle S, Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: A switch in the decision between apoptosis and necrosis. J Exp Med. 1997; 185:1481–1486.
   PubMed Web of Science ®Google Scholar
• Nagy G, Koncz A, Perl A. T cell activation-induced mitochondrial hyperpolarization is mediated by Ca2+- and redox-dependent production of nitric oxide. J Immunol. 2003; 171:5188–5197.
   PubMed Web of Science ®Google Scholar
• Krishnan S, Nambiar MP, Warke VG, Fisher CU, Mitchell J, Delaney N, . Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J Immunol. 2004; 172:782–731.
   Google Scholar
• Nambiar MP, Fisher CU, Enyedy EJ, Warke VG, Kumar A, Tsokos GC. Oxidative stress is involved in the heat stress-induced downregulation of TCR zeta chain expression and TCR/CD3-mediated [Ca(2+)](i) response in human T-lymphocytes. Cell Immunol. 2002; 215 2: 151–161.
   PubMedGoogle Scholar
• Gorelik G, Fang JY, Wu A, Sawalha AH, Richardson B. Impaired T cell protein kinase C{delta} activation decreases ERK pathway signaling in idiopathic and hydralazine-induced lupus. J Immunol. 2007; 179 8: 5553–5563.
   PubMed Web of Science ®Google Scholar
• Pernis AB. Rho GTPase-mediated pathways in mature CD4+T cells. Autoimmun Rev. 2009; 8 3: 199–203.
   PubMedGoogle Scholar
• Bolland S, Ravetch JV. Spontaneous autoimmune disease in Fc[gamma]RIIB-deficient mice results from strain-specific epistasis. Immunity. 2000; 13 2: 277–285.
   PubMed Web of Science ®Google Scholar
• Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, . Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001; 166 1: 6–10.
   PubMed Web of Science ®Google Scholar
• Nisoli E, Carruba MO. Nitric oxide and mitochondrial biogenesis. J Cell Sci. 2006; 119 14: 2855–2862.
   PubMedGoogle Scholar
• Almeida A, Almeida J, Bolanos JP, Moncada S. Different responses of astrocytes and neurons to nitric oxide: The role of glycolytically generated ATP in astrocyte protection. Proc Natl Acad Sci USA. 2001; 98 26: 15294–15299.
   PubMedGoogle Scholar
• Kurosaki T. Regulation of B-cell signal transduction by adaptor proteins. Nat Rev Immunol. 2002; 2 5: 354–363 [Review] [101 refs].
   PubMedGoogle Scholar
• Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003; 3 4: 317–330 [Review]. [151 refs].
   PubMed Web of Science ®Google Scholar
• Gwack Y, Srikanth S, Oh-hora M, Hogan PG, Lamperti ED, Yamashita M, . Hair loss and defective T- and B-cell function in mice lacking ORAI1. Mol Cell Biol. 2008; 28 17: 5209–5222.
   PubMed Web of Science ®Google Scholar
• Yaseen NR, Maizel AL, Wang F, Sharma S. Comparative analysis of NFAT (nuclear factor of activated T cells) complex in human T and B lymphocytes. J Biol Chem. 1993; 268 19: 14285–14293.
   PubMedGoogle Scholar
• Barrington RA, Borde M, Rao A, Carroll MC. Involvement of NFAT1 in B cell self-tolerance. J Immunol. 2006; 177 3: 1510–1515.
   PubMedGoogle Scholar
• Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L, Ford RJ. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood. 2006; 107 11: 4540–4548.
   PubMed Web of Science ®Google Scholar
• Lazzarino DA, Blier P, Mellman I. The monomeric guanosine triphosphatase rab4 controls an essential step on the pathway of receptor-mediated antigen processing in B cells. J Exp Med. 1998; 188:1769–1774.
   PubMed Web of Science ®Google Scholar